Convergent Nodes, Bifurcating Failure: Compartment, Substrate, and the Gate in Glucose Control

Dysglycemia is usually described lesion by lesion — impaired glucose uptake in muscle, unrestrained output in liver — as though these were separate failures. Assembling established biochemistry into a single architecture, we argue instead that they are recurrent expressions of one design: committed nodes that converge multiple inputs and, at a capacity limit, bifurcate — routing load either to an adaptive branch, in which capacity itself expands, or to a collapse branch. Collapse then expresses as two lesions at once, because the node sits at a junction. At the insulin-signaling node, two lipotoxic brakes converge on Akt — diacylglycerol upstream at the receptor–IRS interface, ceramide at the kinase itself — and Akt's collapse appears simultaneously as failed GLUT4 translocation and de-repressed gluconeogenesis. At the fuel-partitioning gate, closure of CPT1 by malonyl-CoA blocks fatty-acid oxidation and forces overflow into the same lipotoxic pool. The adaptive branch is not hypothetical in this domain: metered load enlarges both oxidative capacity and the safe storage sink, and unloaded tissue loses both. The pattern recurs across compartments: the overloaded liver exports both glucose and VLDL-triglyceride, delivering to muscle the very substrate for its ceramide brake. The determinants of node vulnerability are upstream, substrate-dependent, and ordered: substrate species sits above dose and delivery rate, which sit above the membrane environment that sets node geometry, with endocannabinoid set-point tilting the whole landscape. Species is an identity rather than a quantity — palmitate, the precursor of C16:0 ceramide, and the 4,5 backbone double bond that separates a toxic ceramide from an inert dihydroceramide of equal abundance. Because these determinants turn over faster than the erythrocyte-integrated clinical endpoint, the model predicts that upstream correction registers first in a fast glycemic marker and only later in HbA1c — a falsifiable kinetic signature. We offer this as a mechanistic synthesis warranting investigation, not a demonstrated result. Keywords: insulin resistance; ceramide; diacylglycerol; CPT1; malonyl-CoA; endocannabinoid tone; substrate partitioning; hepatic de novo lipogenesis; glycemic kinetics; biochemistry; committed nodes; bifurcating failure; hysteresis; critical slowing; early-warning signals.